Research programme: anti-CD5 monoclonal antibodies - Affimed Therapeutics

Drug Profile

Research programme: anti-CD5 monoclonal antibodies - Affimed Therapeutics

Alternative Names: AFM 16; AFM 17; anti-CD5

Latest Information Update: 22 Jul 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Affimed Therapeutics
  • Class Monoclonal antibodies
  • Mechanism of Action CD5 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Autoimmune disorders; Chronic lymphocytic leukaemia; Multiple myeloma

Most Recent Events

  • 26 Jul 2005 Preclinical trials in Autoimmune disorders in Germany (Injection)
  • 26 Jul 2005 Preclinical trials in Chronic lymphocytic leukaemia in Germany (Injection)
  • 26 Jul 2005 Preclinical trials in Multiple myeloma in Germany (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top